Last reviewed · How we verify

NCT03433131

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

NO LONGER AVAILABLE Last updated 28 August 2019
What this trial tests

trial testing Pitolisant in Narcolepsy Without Cataplexy. No longer available.

Quick facts

Lead sponsorHarmony Biosciences Management, Inc.
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS
Sites71 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Harmony Biosciences Management, Inc. — full company profile →

Who can join

18 and older, any sex, with Narcolepsy Without Cataplexy or Narcolepsy With Cataplexy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This EAP will be open to provide access to treatment with pitolisant while a U.S. New Drug Application (NDA) is being prepared and submitted for review for marketing approval. This program will be open to adult patients in the U.S. with Excessive Daytime Sleepiness (EDS) associated with narcolepsy, with or without cataplexy. Pitolisant will be made available through treating physicians participating in the program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pitolisant

Trials testing the same drug.

Other Harmony Biosciences Management, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03433131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing